Elia Aguado-Fraile

Company: Repare Therapeutics

Job title: Associate Director, Translational Science

Seminars:

Utility of Circulating Tumor DNA (ctDNA) Assessments to Support Early Clinical Development of the PKMYT1 Inhibitor Lunresertib in Combination with the ATR Inhibitor Camonsertib in the Phase I MYTHIC trial 8:30 am

Examining the role of ctDNA assessments in the early clinical development of the lunresertib and camonsertib combination, with a focus on confirmation rates of enrollment alterations Using ctDNA data to support dose and schedule selection for the combination therapy in the Phase I MYTHIC trial Correlating early ctDNA kinetics with clinical outcomes to evaluate the…Read more

day: Day One